Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 9, 1997, Pages 660-668

  Leriche Guerin K ^a   Trabaud, M A ^a   Cotte, L ^b   Bissuel, F ^b   Deruelle, E ^a   Rougier, P ^b   Trepo C ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ARTICLE; CODON; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS RESISTANCE;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RNA, VIRAL; ZIDOVUDINE;

EID: 0030730332     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01708556     Document Type: Article

References (22)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, AZT Collaborative Working Group: The efficacy of azidothimidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 1987, 317: 185-191.
2. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy D, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA, Volverding, P, Petinelli C, Anderson J, AIDS Clinical Trial Group: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1990, 112: 727-737.
3. MacLeod GX, Hammer SM: Zidovudine: five years later. Annals of Internal Medicine 1992, 117: 487-501.
4. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243: 1731-1734.
5. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246: 1155-1158.
6. Boucher CAB, Tersmette M, Lange JMA, Kellam P, de Goede REY, Mulder JW, Darby G, Goudsmit J, Larder BA: Zidovudine sensitivity of human immunodeficiency viruses from high-risk symptom-free individals during therapy. Lancet 1990, 336: 585-590.
7. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5: 137-144.
8. Richman DD: Clinical significance of drug resistance in human immunodeficiency virus. Clinical Infectious Diseases 1995, 21: Supplement 2: 166-169.
9. Montaner JSG, Singer J, Schlechter MT, Raboud JM, Tsoukas C, O'Shaughnessy M, Ruedy J, Nagai K, Salomon H, Spira B, Wainberg MA: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS 1993, 7: 189-196.
10. D'Aquila RT, Johnson V, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD, AIDS Clinical Trials Group Protocol 116B/117 Team, Virology Committee Resistance Working Group: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Annals of Internal Medicine 1995, 122: 401-408.
11. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR: RT prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. Journal of Infectious Diseases 1995, 171: 1172-1179.
12. Calderon EJ, Torres Y, Medrano FJ, Luque F, Larder BA, Rey C, Sanchez-Quijano A, Lissen E, Leal M: Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 512-519.
13. Merigan TC, Hirsch RL, Fisher AC, Meyerson LA, Goldstein G, Winters MA: The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation, and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS 1996, 10: 159-165.
14. Yerly S, Denereaz N, Mermillod B, Hirschel B, Perrin L: Predictive value of codon 215 reverse transcriptase mutation on efficacy of didanosine in HIV-infected, zidovudine-experienced patients. Antiviral Therapy 1996, 1: 167-171.
15. Richman DD, Grimes JM, Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolated human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndrome 1990, 3: 743-746.
16. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 1992, 165: 105-110.
17. Land S, McGavin C, Lucas R, Birch C: Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. Journal of Infectious Diseases 1992, 166: 1139-1142.
18. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, Sacks HS: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS defining illness. A meta-analysis. Annals of Internal Medicine 1995, 122: 856-866.
19. Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, Van Strijp D, Lange J, Koot M, Van Gemen B: Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. AIDS. Research and Human Retroviruses 1995, 11: 473-479.
20. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 1995, 122: 573-579.
21. Tudor-William G, St Clair MH, McKinney RE, Maha M, Walter E, Santacroce S, Mintz M, O'Donnel K, Rudoll T, Vavro CL, Connor EM, Wilfert CM: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339: 15-19.
22. Shepp DH, Ashraf A, Tang ITL, Match ME, Millan C, Pergolizzi R: Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologie response and survival. Journal of Medical Virology 1996, 49: 303-310.